{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:38:31Z","timestamp":1793317111737,"version":"4.5.0"},"reference-count":177,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01944-0","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:04:22Z","timestamp":1764137062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Tumor microenvironment-mediated immune evasion and resistance in prostate cancer: mechanisms, cross-talk, and therapeutic opportunities"],"prefix":"10.1007","volume":"26","author":[{"given":"Mingfeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Boafo","family":"Kwantwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuimei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"1944_CR1","unstructured":"Genitourinary Oncology Committee of Chinese Anti-Cancer A. [Expert consensus on whole-course management of prostate cancer (2025 edition)]. Zhonghua Zhong Liu Za Zhi. 2025; 47:617\u201334."},{"key":"1944_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1944_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/iju.15378","volume":"31","author":"MA De Velasco","year":"2024","unstructured":"De Velasco MA, Kura Y, Fujita K, Uemura H. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer. Int J Urol. 2024;31:307\u201324.","journal-title":"Int J Urol"},{"key":"1944_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194757","author":"M Movassaghi","year":"2021","unstructured":"Movassaghi M, Chung R, Anderson CB, Stein M, Saenger Y, Faiena I. Overcoming immune resistance in prostate cancer: challenges and advances. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13194757.","journal-title":"Cancers (Basel)"},{"key":"1944_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","volume":"24","author":"J Stultz","year":"2021","unstructured":"Stultz J, Fong L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:697\u2013717.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1944_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/aja202283","volume":"25","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Duong L, Lu X, Lu X. Cancer-cell-intrinsic mechanisms shaping the immunosuppressive landscape of prostate cancer. Asian J Androl. 2023;25:171\u20138.","journal-title":"Asian J Androl"},{"key":"1944_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1055826","volume":"13","author":"C Qin","year":"2022","unstructured":"Qin C, Wang J, Du Y, Xu T. Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer. Front Endocrinol (Lausanne). 2022;13:1055826.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1944_CR8","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1080\/14712598.2022.2108701","volume":"22","author":"E Chandran","year":"2022","unstructured":"Chandran E, Meininger L, Karzai F, Madan RA. Signaling new therapeutic opportunities: cytokines in prostate cancer. Expert Opin Biol Ther. 2022;22:1233\u201343.","journal-title":"Expert Opin Biol Ther"},{"key":"1944_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.805459","volume":"11","author":"B Che","year":"2021","unstructured":"Che B, Zhang W, Xu S, Yin J, He J, Huang T, et al. Prostate microbiota and prostate cancer: a new trend in treatment. Front Oncol. 2021;11:805459.","journal-title":"Front Oncol"},{"key":"1944_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081778","author":"P Xu","year":"2022","unstructured":"Xu P, Wasielewski LJ, Yang JC, Cai D, Evans CP, Murphy WJ, et al. The immunotherapy and immunosuppressive signaling in therapy-resistant prostate cancer. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10081778.","journal-title":"Biomedicines"},{"key":"1944_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1158\/1541-7786.MCR-24-0791","volume":"23","author":"S Mei","year":"2025","unstructured":"Mei S, Zhang H, Hirz T, Jeffries NE, Xu Y, Baryawno N, et al. Single-cell and spatial transcriptomics reveal a tumor-associated macrophage subpopulation that mediates prostate cancer progression and metastasis. Mol Cancer Res. 2025;23:653\u201365.","journal-title":"Mol Cancer Res"},{"key":"1944_CR12","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/carcin\/bgaa065","volume":"41","author":"SM Sadasivan","year":"2020","unstructured":"Sadasivan SM, Chen Y, Gupta NS, Han X, Bobbitt KR, Chitale DA, et al. The interplay of growth differentiation factor 15 (GDF15) expression and M2 macrophages during prostate carcinogenesis. Carcinogenesis. 2020;41:1074\u201382.","journal-title":"Carcinogenesis"},{"key":"1944_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12575-024-00247-0","volume":"26","author":"T Cao","year":"2024","unstructured":"Cao T, Sun Q, Shi X, Lin X, Lin Q, Zhu J, et al. EAF2 downregulation recruits tumor-associated macrophages in prostate cancer through upregulation of MIF. Biol Proced Online. 2024;26:21.","journal-title":"Biol Proced Online"},{"key":"1944_CR14","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1158\/1541-7786.MCR-20-0740","volume":"19","author":"JC Siefert","year":"2021","unstructured":"Siefert JC, Cioni B, Muraro MJ, Alshalalfa M, Vivie J, van der Poel HG, et al. The prognostic potential of human prostate cancer-associated macrophage subtypes as revealed by single-cell transcriptomics. Mol Cancer Res. 2021;19:1778\u201391.","journal-title":"Mol Cancer Res"},{"key":"1944_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12865-022-00514-3","volume":"23","author":"Y Peng","year":"2022","unstructured":"Peng Y, Zhao M, Hu Y, Guo H, Zhang Y, Huang Y, et al. Blockade of exosome generation by GW4869 inhibits the education of M2 macrophages in prostate cancer. BMC Immunol. 2022;23:37.","journal-title":"BMC Immunol"},{"key":"1944_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06519-x","volume":"23","author":"R Liu","year":"2025","unstructured":"Liu R, Lu J, Liu J, Liao Y, Guo Y, Shi P, et al. Macrophages in prostate cancer: dual roles in tumor progression and immune evasion. J Transl Med. 2025;23:615.","journal-title":"J Transl Med"},{"key":"1944_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/genes12050773","author":"W Guan","year":"2021","unstructured":"Guan W, Li F, Zhao Z, Zhang Z, Hu J, Zhang Y. Tumor-associated macrophage promotes the survival of cancer cells upon docetaxel chemotherapy via the CSF1\/CSF1R-CXCL12\/CXCR4 axis in castration-resistant prostate cancer. Genes. 2021. https:\/\/doi.org\/10.3390\/genes12050773.","journal-title":"Genes"},{"key":"1944_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1560998","volume":"16","author":"T Wu","year":"2025","unstructured":"Wu T, Li X, Zheng F, Liu H, Yu Y. Intercellular communication between FAP+ fibroblasts and SPP1+ macrophages in prostate cancer via multi-omics. Front Immunol. 2025;16:1560998.","journal-title":"Front Immunol"},{"key":"1944_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41419-020-2435-y","volume":"11","author":"R Huang","year":"2020","unstructured":"Huang R, Wang S, Wang N, Zheng Y, Zhou J, Yang B, et al. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating beta-catenin\/STAT3 signaling. Cell Death Dis. 2020;11:234.","journal-title":"Cell Death Dis"},{"key":"1944_CR20","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1002\/cbin.11630","volume":"45","author":"J Ma","year":"2021","unstructured":"Ma J, Shayiti F, Ma J, Wei M, Hua T, Zhang R, et al. Tumor-associated macrophage-derived CCL5 promotes chemotherapy resistance and metastasis in prostatic cancer. Cell Biol Int. 2021;45:2054\u201362.","journal-title":"Cell Biol Int"},{"key":"1944_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01497-21","volume":"9","author":"S Davidsson","year":"2021","unstructured":"Davidsson S, Carlsson J, Greenberg L, Wijkander J, Soderquist B, Erlandsson A. Cutibacterium acnes induces the expression of immunosuppressive genes in macrophages and is associated with an increase of regulatory T-Cells in prostate cancer. Microbiol Spectr. 2021;9:e0149721.","journal-title":"Microbiol Spectr"},{"key":"1944_CR22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373:428\u201337.","journal-title":"N Engl J Med"},{"key":"1944_CR23","doi-asserted-by":"publisher","first-page":"27467","DOI":"10.1038\/s41598-025-10624-8","volume":"15","author":"W Shan","year":"2025","unstructured":"Shan W, Guan B, Ma W, Fan R, Cui D, Hao Z. Comprehensive single-cell transcriptomic analysis reveals fibroblast subpopulations and the prognostic association of COMT in prostate cancer progression, COMT. COMT Sci Rep. 2025;15:27467.","journal-title":"COMT Sci Rep"},{"key":"1944_CR24","doi-asserted-by":"publisher","first-page":"1133160","DOI":"10.3389\/fimmu.2023.1133160","volume":"14","author":"J Pan","year":"2023","unstructured":"Pan J, Ma Z, Liu B, Qian H, Shao X, Liu J, et al. Identification of cancer-associated fibroblasts subtypes in prostate cancer. Front Immunol. 2023;14:1133160.","journal-title":"Front Immunol"},{"key":"1944_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034611","volume":"102","author":"W Liu","year":"2023","unstructured":"Liu W, Wang M, Wang M, Liu M. Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer. Medicine (Baltimore). 2023;102:e34611.","journal-title":"Medicine (Baltimore)"},{"key":"1944_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/cjp2.205","volume":"7","author":"AB Hesterberg","year":"2021","unstructured":"Hesterberg AB, Rios BL, Wolf EM, Tubbs C, Wong HY, Schaffer KR, et al. A distinct repertoire of cancer-associated fibroblasts is enriched in cribriform prostate cancer. J Pathol Clin Res. 2021;7:271\u201386.","journal-title":"J Pathol Clin Res"},{"key":"1944_CR27","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1186\/s12885-025-14212-x","volume":"25","author":"Y Qiu","year":"2025","unstructured":"Qiu Y, Wang Y, Liu J, Sun K, Liu B, Hou Q. Single-cell sequencing unveils the transcriptomic landscape of castration-resistant prostate cancer-associated fibroblasts and their association with prognosis and immunotherapy response. BMC Cancer. 2025;25:813.","journal-title":"BMC Cancer"},{"key":"1944_CR28","doi-asserted-by":"publisher","first-page":"1582992","DOI":"10.3389\/fimmu.2025.1582992","volume":"16","author":"W Li","year":"2025","unstructured":"Li W, Wei X, Yu Y, Tian Y, Yu Q, Qiao J, et al. Landscape analysis of matrix metalloproteinases reveals key prognostic markers for prostate cancer. Front Immunol. 2025;16:1582992.","journal-title":"Front Immunol"},{"key":"1944_CR29","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s00262-023-03378-7","volume":"72","author":"N Nishiwaki","year":"2023","unstructured":"Nishiwaki N, Noma K, Ohara T, Kunitomo T, Kawasaki K, Akai M, et al. Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody. Cancer Immunol Immunother. 2023;72:2029\u201344.","journal-title":"Cancer Immunol Immunother"},{"key":"1944_CR30","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/s41388-024-03057-6","volume":"43","author":"J Zhao","year":"2024","unstructured":"Zhao J, Shen J, Mao L, Yang T, Liu J, Hongbin S. Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer. Oncogene. 2024;43:2104\u201314.","journal-title":"Oncogene"},{"key":"1944_CR31","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1038\/s41467-022-33780-1","volume":"13","author":"HY Wong","year":"2022","unstructured":"Wong HY, Sheng Q, Hesterberg AB, Croessmann S, Rios BL, Giri K, et al. Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. Nat Commun. 2022;13:6036.","journal-title":"Nat Commun"},{"key":"1944_CR32","doi-asserted-by":"publisher","first-page":"9050","DOI":"10.1038\/s41467-024-53233-1","volume":"15","author":"K Zhang","year":"2024","unstructured":"Zhang K, Liu K, Hu B, Du G, Chen X, Xiao L, et al. Iron-loaded cancer-associated fibroblasts induce immunosuppression in prostate cancer. Nat Commun. 2024;15:9050.","journal-title":"Nat Commun"},{"key":"1944_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5455\/aim.2021.29.182-186","volume":"29","author":"KP Seputra","year":"2021","unstructured":"Seputra KP, Kalim H, Susianti H, Purnomo BB, Al Rasyid H, Purnomo AF. Modulation of T-cell regulators associated with advanced stage of prostate cancer. Acta Inform Med. 2021;29:182\u20136.","journal-title":"Acta Inform Med"},{"key":"1944_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/path.5757","volume":"255","author":"LB Andersen","year":"2021","unstructured":"Andersen LB, Norgaard M, Rasmussen M, Fredsoe J, Borre M, Ulhoi BP, et al. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors. J Pathol. 2021;255:155\u201365.","journal-title":"J Pathol"},{"key":"1944_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119132","volume":"284","author":"V Karpisheh","year":"2021","unstructured":"Karpisheh V, Mousavi SM, Naghavi Sheykholeslami P, Fathi M, Mohammadpour Saray M, Aghebati-Maleki L, et al. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. Life Sci. 2021;284:119132.","journal-title":"Life Sci"},{"key":"1944_CR36","doi-asserted-by":"publisher","first-page":"1157345","DOI":"10.3389\/fonc.2023.1157345","volume":"13","author":"Q Li","year":"2023","unstructured":"Li Q, Lu J, Li J, Zhang B, Wu Y, Ying T. Antibody-based cancer immunotherapy by targeting regulatory T cells. Front Oncol. 2023;13:1157345.","journal-title":"Front Oncol"},{"key":"1944_CR37","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1159\/000541881","volume":"103","author":"R Novysedlak","year":"2025","unstructured":"Novysedlak R, Guney M, Al Khouri M, Bartolini R, Koumbas Foley L, Benesova I, et al. The immune microenvironment in prostate cancer: a comprehensive review. Oncology. 2025;103:521\u201345.","journal-title":"Oncology"},{"key":"1944_CR38","doi-asserted-by":"publisher","first-page":"1626708","DOI":"10.3389\/fimmu.2025.1626708","volume":"16","author":"J Li","year":"2025","unstructured":"Li J, Zhang L, Liu R, Xu C, Tang H, Zou Y, et al. CXCL12\/CXCR4 axis governs Treg spatial dominance over CD8+ T cells via IL-2 sequestration: a dual therapeutic target in prostate cancer. Front Immunol. 2025;16:1626708.","journal-title":"Front Immunol"},{"key":"1944_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003731","author":"S Maeda","year":"2022","unstructured":"Maeda S, Motegi T, Iio A, Kaji K, Goto-Koshino Y, Eto S, et al. Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003731.","journal-title":"J Immunother Cancer"},{"key":"1944_CR40","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.09.24313308","author":"CR Ager","year":"2025","unstructured":"Ager CR, Obradovic A, McCann P, Chaimowitz M, Wang ALE, Shaikh N, et al. Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer. Medrxiv. 2025. https:\/\/doi.org\/10.1101\/2024.09.09.24313308.","journal-title":"Medrxiv."},{"key":"1944_CR41","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1007\/s00262-021-02915-6","volume":"70","author":"K Witt","year":"2021","unstructured":"Witt K, Evans-Axelsson S, Lundqvist A, Johansson M, Bjartell A, Hellsten R. Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer. Cancer Immunol Immunother. 2021;70:3155\u201366.","journal-title":"Cancer Immunol Immunother"},{"key":"1944_CR42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI169655","author":"P Zanvit","year":"2023","unstructured":"Zanvit P, van Dyk D, Fazenbaker C, McGlinchey K, Luo W, Pezold JM, et al. Antitumor activity of AZD0754, a dnTGFbetaRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI169655.","journal-title":"J Clin Invest"},{"key":"1944_CR43","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28:724\u201334.","journal-title":"Nat Med"},{"key":"1944_CR44","doi-asserted-by":"publisher","first-page":"694","DOI":"10.37349\/etat.2022.00108","volume":"3","author":"MT Palano","year":"2022","unstructured":"Palano MT, Gallazzi M, Cucchiara M, Deho F, Capogrosso P, Bruno A, et al. The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors. Explor Target Antitumor Ther. 2022;3:694\u2013718.","journal-title":"Explor Target Antitumor Ther"},{"key":"1944_CR45","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/cbin.11651","volume":"45","author":"MJ Sanaei","year":"2021","unstructured":"Sanaei MJ, Taheri F, Heshmati M, Bashash D, Nazmabadi R, Mohammad-Alibeigi F, et al. Comparing the frequency of CD33(+) pSTAT3(+) myeloid-derived suppressor cells and IL-17(+) lymphocytes in patients with prostate cancer and benign prostatic hyperplasia. Cell Biol Int. 2021;45:2086\u201395.","journal-title":"Cell Biol Int"},{"key":"1944_CR46","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.7150\/jca.81933","volume":"14","author":"W Xu","year":"2023","unstructured":"Xu W, Lu M, Xie S, Zhou D, Zhu M, Liang C. Endoplasmic reticulum stress promotes prostate cancer cells to release exosome and up-regulate PD-L1 expression via PI3K\/Akt signaling pathway in macrophages. J Cancer. 2023;14:1062\u201374.","journal-title":"J Cancer"},{"key":"1944_CR47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12964-020-00589-8","volume":"18","author":"Q Hao","year":"2020","unstructured":"Hao Q, Vadgama JV, Wang P. CCL2\/CCR2 signaling in cancer pathogenesis. Cell Commun Signal. 2020;18:82.","journal-title":"Cell Commun Signal"},{"key":"1944_CR48","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1038\/s41388-022-02423-6","volume":"41","author":"X Wang","year":"2022","unstructured":"Wang X, Brea L, Lu X, Gritsina G, Park SH, Xie W, et al. FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A. Oncogene. 2022;41:4259\u201370.","journal-title":"Oncogene"},{"key":"1944_CR49","doi-asserted-by":"publisher","DOI":"10.1101\/2023.12.01.569685","author":"K Sha","year":"2024","unstructured":"Sha K, Zhang R, Maolake A, Singh S, Chatta G, Eng KH, et al. Androgen deprivation triggers a cytokine signaling switch to induce immune suppression and prostate cancer recurrence. Biorxiv. 2024. https:\/\/doi.org\/10.1101\/2023.12.01.569685.","journal-title":"Biorxiv."},{"key":"1944_CR50","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5584406","volume":"2021","author":"N Li","year":"2021","unstructured":"Li N, Wang Y, Xu H, Wang H, Gao Y, Zhang Y. Exosomes derived from RM-1 cells promote the recruitment of MDSCs into tumor microenvironment by upregulating CXCR4 via TLR2\/NF-kappaB pathway. J Oncol. 2021;2021:5584406.","journal-title":"J Oncol"},{"key":"1944_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47633-4","volume":"13","author":"B Govindarajan","year":"2023","unstructured":"Govindarajan B, Sbrissa D, Pressprich M, Kim S, Rishi AK, Vaishampayan U, et al. Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth. Sci Rep. 2023;13:20634.","journal-title":"Sci Rep"},{"key":"1944_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2025.114680","volume":"450","author":"Z Liu","year":"2025","unstructured":"Liu Z, Tian Y, Li Z, Li Z, Yang K, Zeng Y, et al. Neutrophil-mediated alteration of CXCL1\/IL-8\/AR signaling promotes prostate cancer cell proliferation. Exp Cell Res. 2025;450:114680.","journal-title":"Exp Cell Res"},{"key":"1944_CR53","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.3390\/ijms24087262","volume":"24","author":"J Korbecki","year":"2023","unstructured":"Korbecki J, Bosiacki M, Barczak K, Lagocka R, Brodowska A, Chlubek D, et al. Involvement in tumorigenesis and clinical significance of cxcl1 in reproductive cancers: breast cancer, cervical cancer, endometrial cancer, ovarian cancer and prostate cancer. Int J Mol Sci. 2023;24:7262.","journal-title":"Int J Mol Sci"},{"issue":"1464\u201378","key":"1944_CR54","volume":"39","author":"Y Kfoury","year":"2021","unstructured":"Kfoury Y, Baryawno N, Severe N, Mei S, Gustafsson K, Hirz T, et al. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell. 2021;39(1464\u201378):e8.","journal-title":"Cancer Cell"},{"key":"1944_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.155916","volume":"269","author":"V Fiorentino","year":"2025","unstructured":"Fiorentino V, Pepe L, Pizzimenti C, Zuccala V, Pepe P, Cianci V, et al. PD-L1 expression in prostate cancer and Gleason Grade Group: is there any relationship? Findings from a multi-institutional cohort. Pathol Res Pract. 2025;269:155916.","journal-title":"Pathol Res Pract"},{"key":"1944_CR56","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40487-022-00184-6","volume":"10","author":"P Katongole","year":"2022","unstructured":"Katongole P, Sande OJ, Reynolds SJ, Joloba M, Kajumbula H, Kalungi S, et al. Soluble programmed death-ligand 1 (sPD-L1) is elevated in aggressive prostate cancer disease among African men. Oncol Ther. 2022;10:185\u201393.","journal-title":"Oncol Ther"},{"key":"1944_CR57","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12957-021-02325-z","volume":"19","author":"J He","year":"2021","unstructured":"He J, Yi M, Tan L, Huang J, Huang L. The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer. World J Surg Oncol. 2021;19:215.","journal-title":"World J Surg Oncol"},{"key":"1944_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11121312","author":"A Palicelli","year":"2021","unstructured":"Palicelli A, Bonacini M, Croci S, Bisagni A, Zanetti E, De Biase D, et al. What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 7: PD-L1 expression in liquid biopsy. J Pers Med. 2021. https:\/\/doi.org\/10.3390\/jpm11121312.","journal-title":"J Pers Med"},{"key":"1944_CR59","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40364-021-00267-y","volume":"9","author":"T Zhang","year":"2021","unstructured":"Zhang T, Agarwal A, Almquist RG, Runyambo D, Park S, Bronson E, et al. Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. Biomark Res. 2021;9:14.","journal-title":"Biomark Res"},{"key":"1944_CR60","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","volume":"23","author":"Q Liu","year":"2024","unstructured":"Liu Q, Guan Y, Li S. Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers\u202f: the \u201call-around warrior\u201d in immunotherapy. Mol Cancer. 2024;23:183.","journal-title":"Mol Cancer"},{"key":"1944_CR61","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1080\/07853890.2021.1924396","volume":"53","author":"Z JiaWei","year":"2021","unstructured":"JiaWei Z, ChunXia D, CunDong L, Yang L, JianKun Y, HaiFeng D, et al. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer. Ann Med. 2021;53:730\u201340.","journal-title":"Ann Med"},{"key":"1944_CR62","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","volume":"28","author":"T Powles","year":"2022","unstructured":"Powles T, Yuen KC, Gillessen S, Kadel EE 3rd, Rathkopf D, Matsubara N, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28:144\u201353.","journal-title":"Nat Med"},{"key":"1944_CR63","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2426755","volume":"57","author":"Z Wu","year":"2025","unstructured":"Wu Z, Zhang J, Li L, Wang Z, Yang C. Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors. Ann Med. 2025;57:2426755.","journal-title":"Ann Med"},{"key":"1944_CR64","doi-asserted-by":"publisher","first-page":"1181051","DOI":"10.3389\/fimmu.2023.1181051","volume":"14","author":"M Noori","year":"2023","unstructured":"Noori M, Azizi S, Mahjoubfar A, Abbasi Varaki F, Fayyaz F, Mousavian AH, et al. Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis. Front Immunol. 2023;14:1181051.","journal-title":"Front Immunol"},{"key":"1944_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006581","author":"P Xu","year":"2023","unstructured":"Xu P, Yang JC, Chen B, Nip C, Van Dyke JE, Zhang X, et al. Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-006581.","journal-title":"J Immunother Cancer"},{"key":"1944_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001758","author":"Z Wang","year":"2021","unstructured":"Wang Z, Zhang X, Li W, Su Q, Huang Z, Zhang X, et al. ATM\/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-001758.","journal-title":"J Immunother Cancer"},{"key":"1944_CR67","doi-asserted-by":"publisher","first-page":"175883592093608","DOI":"10.1177\/1758835920936084","volume":"12","author":"HJ Han","year":"2020","unstructured":"Han HJ, Li YR, Roach M 3rd, Aggarwal R. Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer. Ther Adv Med Oncol. 2020;12:1758835920936084.","journal-title":"Ther Adv Med Oncol"},{"key":"1944_CR68","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1007\/s12094-022-02779-x","volume":"24","author":"NK Sedky","year":"2022","unstructured":"Sedky NK, Hamdan AA, Emad S, Allam AL, Ali M, Tolba MF. Insights into the therapeutic potential of histone deacetylase inhibitor\/immunotherapy combination regimens in solid tumors. Clin Transl Oncol. 2022;24:1262\u201373.","journal-title":"Clin Transl Oncol"},{"key":"1944_CR69","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1007\/s00018-020-03459-1","volume":"77","author":"S Jafari","year":"2020","unstructured":"Jafari S, Molavi O, Kahroba H, Hejazi MS, Maleki-Dizaji N, Barghi S, et al. Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer. Cell Mol Life Sci. 2020;77:3693\u2013710.","journal-title":"Cell Mol Life Sci"},{"key":"1944_CR70","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.7150\/jca.51173","volume":"12","author":"H Zhao","year":"2021","unstructured":"Zhao H, Zhang X, Shi Z, Guo B, Zhang W, He K, et al. Identification of a prognostic signature model with tumor microenvironment for predicting disease-free survival after radical prostatectomy. J Cancer. 2021;12:2371\u201384.","journal-title":"J Cancer"},{"key":"1944_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102057","volume":"88","author":"M Claps","year":"2020","unstructured":"Claps M, Mennitto A, Guadalupi V, Sepe P, Stellato M, Zattarin E, et al. Immune-checkpoint inhibitors and metastatic prostate cancer therapy: learning by making mistakes. Cancer Treat Rev. 2020;88:102057.","journal-title":"Cancer Treat Rev"},{"issue":"489\u201399","key":"1944_CR72","volume":"38","author":"P Sharma","year":"2020","unstructured":"Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the checkmate 650 trial. Cancer Cell. 2020;38(489\u201399):e3.","journal-title":"Cancer Cell"},{"key":"1944_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002919","author":"SK Subudhi","year":"2021","unstructured":"Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, et al. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naive metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002919.","journal-title":"J Immunother Cancer"},{"key":"1944_CR74","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/bju.16496","volume":"135","author":"B Geboers","year":"2025","unstructured":"Geboers B, Scheltema MJ, Jung J, Bakker J, Timmer FEF, Cerutti X, et al. Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO study. BJU Int. 2025;135:319\u201328.","journal-title":"BJU Int"},{"key":"1944_CR75","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf6724","volume":"15","author":"W Shi","year":"2023","unstructured":"Shi W, Wang Y, Zhao Y, Kim JJ, Li H, Meng C, et al. Immune checkpoint B7\u2013H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Sci Transl Med. 2023;15:eadf6724.","journal-title":"Sci Transl Med"},{"key":"1944_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.693321","volume":"11","author":"XY Tang","year":"2021","unstructured":"Tang XY, Shi AP, Xiong YL, Zheng KF, Liu YJ, Shi XG, et al. Clinical research on the mechanisms underlying immune checkpoints and tumor metastasis. Front Oncol. 2021;11:693321.","journal-title":"Front Oncol"},{"key":"1944_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00323-2","volume":"6","author":"X Shi","year":"2022","unstructured":"Shi X, Day A, Bergom HE, Tape S, Baca SC, Sychev ZE, et al. Integrative molecular analyses define correlates of high B7\u2013H3 expression in metastatic castrate-resistant prostate cancer. NPJ Precis Oncol. 2022;6:80.","journal-title":"NPJ Precis Oncol"},{"key":"1944_CR78","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01674-x","volume":"15","author":"Q Shen","year":"2024","unstructured":"Shen Q, Zhou K, Lu H, Zhang J, Xu Q, Zhang C, et al. Immune checkpoint B7\u2013H3 is a potential therapeutic target in prostate cancer. Discov Oncol. 2024;15:822.","journal-title":"Discov Oncol"},{"key":"1944_CR79","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/pros.24180","volume":"81","author":"CE Nunes-Xavier","year":"2021","unstructured":"Nunes-Xavier CE, Kildal W, Kleppe A, Danielsen HE, Waehre H, Llarena R, et al. Immune checkpoint B7\u2013H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer. Prostate. 2021;81:838\u201348.","journal-title":"Prostate"},{"key":"1944_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133473","author":"P Chetta","year":"2023","unstructured":"Chetta P, Sriram R, Zadra G. Lactate as key metabolite in prostate cancer progression: what are the clinical implications? Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15133473.","journal-title":"Cancers (Basel)"},{"key":"1944_CR81","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/0008-5472.CAN-21-0914","volume":"82","author":"L Ippolito","year":"2022","unstructured":"Ippolito L, Comito G, Parri M, Iozzo M, Duatti A, Virgilio F, et al. Lactate rewires lipid metabolism and sustains a metabolic-epigenetic axis in prostate cancer. Cancer Res. 2022;82:1267\u201382.","journal-title":"Cancer Res"},{"key":"1944_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223861","author":"S Han","year":"2024","unstructured":"Han S, Park S, Kim S, Kwon S, Ko J. Small leucine zipper protein regulates glucose metabolism of prostate cancer cells via induction of phosphoglycerate kinase 1. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16223861.","journal-title":"Cancers (Basel)"},{"key":"1944_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165894","volume":"1866","author":"A Pereira-Nunes","year":"2020","unstructured":"Pereira-Nunes A, Simoes-Sousa S, Pinheiro C, Miranda-Goncalves V, Granja S, Baltazar F. Targeting lactate production and efflux in prostate cancer. Biochimica et Biophysica Acta (BBA). 2020;1866:165894.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"1944_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071064","author":"WA Kwon","year":"2025","unstructured":"Kwon WA, Joung JY. Immunotherapy in prostate cancer: from a \u201ccold\u201d tumor to a \u201chot\u201d prospect. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17071064.","journal-title":"Cancers (Basel)"},{"key":"1944_CR85","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.matbio.2023.06.002","volume":"121","author":"HC Pruitt","year":"2023","unstructured":"Pruitt HC, Guan Y, Liu H, Carey AE, Brennen WN, Lu J, et al. Collagen VI deposition mediates stromal T cell trapping through inhibition of T cell motility in the prostate tumor microenvironment. Matrix Biol. 2023;121:90\u2013104.","journal-title":"Matrix Biol"},{"key":"1944_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111061","author":"IP Pavlova","year":"2021","unstructured":"Pavlova IP, Nair SS, Lundon D, Sobotka S, Roshandel R, Treacy PJ, et al. Multiphoton microscopy for identifying collagen signatures associated with biochemical recurrence in prostate cancer patients. J Pers Med. 2021. https:\/\/doi.org\/10.3390\/jpm11111061.","journal-title":"J Pers Med"},{"key":"1944_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215553","author":"W Ageeli","year":"2021","unstructured":"Ageeli W, Zhang X, Ogbonnaya CN, Ling Y, Wilson J, Li C, et al. Characterisation of collagen re-modelling in localised prostate cancer using second-generation harmonic imaging and transrectal ultrasound shear wave elastography. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13215553.","journal-title":"Cancers (Basel)"},{"key":"1944_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.733561","volume":"12","author":"SV Vijver","year":"2021","unstructured":"Vijver SV, Singh A, Mommers-Elshof E, Meeldijk J, Copeland R, Boon L, et al. Collagen fragments produced in cancer mediate T cell suppression through leukocyte-associated immunoglobulin-like receptor 1. Front Immunol. 2021;12:733561.","journal-title":"Front Immunol"},{"key":"1944_CR89","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2174\/1568009623666230817101809","volume":"24","author":"C Wang","year":"2024","unstructured":"Wang C, Wang J, Chen S, Li K, Wan S, Yang L. COL10A1 as a prognostic biomarker in association with immune infiltration in prostate cancer. Curr Cancer Drug Targets. 2024;24:340\u201353.","journal-title":"Curr Cancer Drug Targets"},{"key":"1944_CR90","doi-asserted-by":"publisher","DOI":"10.1088\/1758-5090\/acd960","author":"K Xu","year":"2023","unstructured":"Xu K, Huang Y, Wu M, Yin J, Wei P. 3D bioprinting of multi-cellular tumor microenvironment for prostate cancer metastasis. Biofabrication. 2023. https:\/\/doi.org\/10.1088\/1758-5090\/acd960.","journal-title":"Biofabrication"},{"key":"1944_CR91","doi-asserted-by":"publisher","first-page":"203","DOI":"10.21873\/cgp.20375","volume":"20","author":"A Minato","year":"2023","unstructured":"Minato A, Kudo Y, Noguchi H, Kohi S, Hasegawa Y, Sato N, et al. Receptor for hyaluronic acid-mediated motility (RHAMM) is associated with prostate cancer migration and poor prognosis. Cancer Genomics Proteomics. 2023;20:203\u201310.","journal-title":"Cancer Genomics Proteomics"},{"key":"1944_CR92","first-page":"251","volume":"23","author":"HAS Albdairi","year":"2025","unstructured":"Albdairi HAS, Colagar AH. Variation of the encoding hyaluronic receptors Hyaluronan-mediated motility receptor (rs299295) and Stabilin-2 (rs2271637) genes with prostate neoplasms risk: a case-control and in silico study. Int J Reprod BioMed (IJRM). 2025;23:251\u201364.","journal-title":"Int J Reprod BioMed (IJRM)"},{"key":"1944_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113424","volume":"42","author":"F Xu","year":"2023","unstructured":"Xu F, Wang X, Huang Y, Zhang X, Sun W, Du Y, et al. Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8(+) T cell. Cell Rep. 2023;42:113424.","journal-title":"Cell Rep"},{"key":"1944_CR94","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1038\/s41388-025-03417-w","volume":"44","author":"J Liu","year":"2025","unstructured":"Liu J, Wang X, He D, Maasoumyhaghighi H, Nouri M, Wu M, et al. Therapeutic targeting of the p300\/CBP bromodomain enhances the efficacy of immune checkpoint blockade therapy. Oncogene. 2025;44:2386\u201395.","journal-title":"Oncogene"},{"key":"1944_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155471","volume":"141","author":"M Macias","year":"2021","unstructured":"Macias M, Garcia-Cortes A, Torres M, Ancizu-Marckert J, Ignacio Pascual J, Diez-Caballero F, et al. Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients. Cytokine. 2021;141:155471.","journal-title":"Cytokine"},{"key":"1944_CR96","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12935-020-01686-x","volume":"21","author":"Y Dai","year":"2021","unstructured":"Dai Y, Gao X. Inhibition of cancer cell-derived exosomal microRNA-183 suppresses cell growth and metastasis in prostate cancer by upregulating TPM1. Cancer Cell Int. 2021;21:145.","journal-title":"Cancer Cell Int"},{"key":"1944_CR97","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8058770","volume":"2022","author":"Z Guo","year":"2022","unstructured":"Guo Z, Lu X, Yang F, He C, Qin L, Yang N, et al. Exosomal LINC01213 plays a role in the transition of androgen-dependent prostate cancer cells into androgen-independent manners. J Oncol. 2022;2022:8058770.","journal-title":"J Oncol"},{"key":"1944_CR98","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/biof.2036","volume":"50","author":"MB Pirouzpanah","year":"2024","unstructured":"Pirouzpanah MB, Babaie S, Pourzeinali S, Valizadeh H, Malekeh S, Sahin F, et al. Harnessing tumor-derived exosomes: a promising approach for the expansion of clinical diagnosis, prognosis, and therapeutic outcome of prostate cancer. BioFactors. 2024;50:674\u201392.","journal-title":"BioFactors"},{"key":"1944_CR99","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1080\/10717544.2022.2044937","volume":"29","author":"D Wang","year":"2022","unstructured":"Wang D, Wan Z, Yang Q, Chen J, Liu Y, Lu F, et al. Sonodynamical reversion of immunosuppressive microenvironment in prostate cancer via engineered exosomes. Drug Deliv. 2022;29:702\u201313.","journal-title":"Drug Deliv"},{"key":"1944_CR100","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13619-024-00206-w","volume":"13","author":"Z Li","year":"2024","unstructured":"Li Z, Li Z, Luo Y, Chen W, Fang Y, Xiong Y, et al. Application and new findings of scRNA-seq and ST-seq in prostate cancer. Cell Regen. 2024;13:23.","journal-title":"Cell Regen"},{"key":"1944_CR101","doi-asserted-by":"publisher","first-page":"1285540","DOI":"10.3389\/fimmu.2023.1285540","volume":"14","author":"S Chen","year":"2023","unstructured":"Chen S, Zhou Z, Li Y, Du Y, Chen G. Application of single-cell sequencing to the research of tumor microenvironment. Front Immunol. 2023;14:1285540.","journal-title":"Front Immunol"},{"key":"1944_CR102","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41420-021-00556-3","volume":"7","author":"J Pu","year":"2021","unstructured":"Pu J, Xu Z, Nian J, Fang Q, Yang M, Huang Y, et al. M2 macrophage-derived extracellular vesicles facilitate CD8+T cell exhaustion in hepatocellular carcinoma via the miR-21-5p\/YOD1\/YAP\/\u03b2-catenin pathway. Cell death discovery. 2021;7:182.","journal-title":"Cell death discovery"},{"key":"1944_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112599","volume":"138","author":"B Guan","year":"2024","unstructured":"Guan B, Huang C, Meng L, Zhang S, Liu Q, Wang X, et al. Dissecting prostate cancer: single-cell insight into macrophage diversity, molecular prognosticators, and the role of peptidylprolyl isomerase F. Int Immunopharmacol. 2024;138:112599.","journal-title":"Int Immunopharmacol"},{"key":"1944_CR104","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00262-024-03633-5","volume":"73","author":"Z Kang","year":"2024","unstructured":"Kang Z, Zhao YX, Qiu RSQ, Chen DN, Zheng QS, Xue XY, et al. Identification macrophage signatures in prostate cancer by single-cell sequencing and machine learning. Cancer Immunol Immunother. 2024;73:41.","journal-title":"Cancer Immunol Immunother"},{"key":"1944_CR105","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202305724","volume":"11","author":"X Bian","year":"2024","unstructured":"Bian X, Wang W, Abudurexiti M, Zhang X, Ma W, Shi G, et al. Integration analysis of single-cell multi-omics reveals prostate cancer heterogeneity. Adv Sci. 2024;11:e2305724.","journal-title":"Adv Sci"},{"key":"1944_CR106","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:663.","journal-title":"Nat Commun"},{"key":"1944_CR107","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395\u2013405.","journal-title":"J Clin Oncol"},{"key":"1944_CR108","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","volume":"35","author":"TM Beer","year":"2017","unstructured":"Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of Ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35:40\u20137.","journal-title":"J Clin Oncol"},{"key":"1944_CR109","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","volume":"29","author":"E Shenderov","year":"2023","unstructured":"Shenderov E, De Marzo AM, Lotan TL, Wang H, Chan S, Lim SJ, et al. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nat Med. 2023;29:888\u201397.","journal-title":"Nat Med"},{"key":"1944_CR110","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, et al. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019;37:946\u201353.","journal-title":"J Clin Oncol"},{"key":"1944_CR111","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma. Cancer Discov. 2018;8:944\u201357.","journal-title":"Cancer Discov"},{"key":"1944_CR112","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","volume":"30","author":"T Dorff","year":"2024","unstructured":"Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, et al. A phase I study of Acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2024;30:1488\u2013500.","journal-title":"Clin Cancer Res"},{"key":"1944_CR113","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med"},{"key":"1944_CR114","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.18.02031","volume":"37","author":"JL Gulley","year":"2019","unstructured":"Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37:1051\u201361.","journal-title":"J Clin Oncol"},{"key":"1944_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217155","volume":"601","author":"D Liu","year":"2024","unstructured":"Liu D, Wang L, Guo Y. Advances in and prospects of immunotherapy for prostate cancer. Cancer Lett. 2024;601:217155.","journal-title":"Cancer Lett"},{"key":"1944_CR116","doi-asserted-by":"publisher","first-page":"656","DOI":"10.20517\/cdr.2023.48","volume":"6","author":"K Sooi","year":"2023","unstructured":"Sooi K, Walsh R, Kumarakulasinghe N, Wong A, Ngoi N. A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer. Cancer Drug Resist. 2023;6:656\u201373.","journal-title":"Cancer Drug Resist"},{"key":"1944_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030537","author":"F Lopez-Campos","year":"2022","unstructured":"Lopez-Campos F, Gajate P, Romero-Laorden N, Zafra-Martin J, Juan M, Hernando Polo S, et al. Immunotherapy in advanced prostate cancer: current knowledge and future directions. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10030537.","journal-title":"Biomedicines"},{"key":"1944_CR118","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00259-025-07099-0","volume":"52","author":"C Miao","year":"2025","unstructured":"Miao C, Yao F, Fang J, Tong Y, Lin H, Lu C, et al. Exploring the role of multimodal [(18)F]F-PSMA-1007 PET\/CT and multiparametric MRI data in predicting ISUP grading of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52:2087\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1944_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0323752","volume":"20","author":"H Zhou","year":"2025","unstructured":"Zhou H, Xie M, Shi H, Shou C, Tang M, Zhang Y, et al. Integrating multimodal imaging and peritumoral features for enhanced prostate cancer diagnosis: a machine learning approach. PLoS ONE. 2025;20:e0323752.","journal-title":"PLoS ONE"},{"key":"1944_CR120","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1158\/1078-0432.CCR-20-4217","volume":"27","author":"RK Pachynski","year":"2021","unstructured":"Pachynski RK, Kim EH, Miheecheva N, Kotlov N, Ramachandran A, Postovalova E, et al. Single-cell spatial proteomic revelations on the multiparametric MRI heterogeneity of clinically significant prostate cancer. Clin Cancer Res. 2021;27:3478\u201390.","journal-title":"Clin Cancer Res"},{"key":"1944_CR121","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.3390\/curroncol31110530","volume":"31","author":"H Takeda","year":"2024","unstructured":"Takeda H, Akatsuka J, Kiriyama T, Toyama Y, Numata Y, Morikawa H, et al. Clinically significant prostate cancer prediction using multimodal deep learning with prostate-specific antigen restriction. Curr Oncol. 2024;31:7180\u20139.","journal-title":"Curr Oncol"},{"key":"1944_CR122","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/978-3-030-42618-7_22","volume":"216","author":"W Weber","year":"2020","unstructured":"Weber W. Clinical PET\/MR. Rec Res Cancer Res. 2020;216:747\u201364.","journal-title":"Rec Res Cancer Res"},{"key":"1944_CR123","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202201334","volume":"18","author":"S Li","year":"2022","unstructured":"Li S, Li Q, Chen W, Song Z, An Y, Chen P, et al. A renal-clearable activatable molecular probe for fluoro-photacoustic and radioactive imaging of cancer biomarkers. Small. 2022;18:e2201334.","journal-title":"Small"},{"key":"1944_CR124","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1039\/D1AN00075F","volume":"146","author":"T Doherty","year":"2021","unstructured":"Doherty T, McKeever S, Al-Attar N, Murphy T, Aura C, Rahman A, et al. Feature fusion of Raman chemical imaging and digital histopathology using machine learning for prostate cancer detection. Analyst. 2021;146:4195\u2013211.","journal-title":"Analyst"},{"key":"1944_CR125","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1021\/jasms.2c00254","volume":"34","author":"MIU Haque","year":"2023","unstructured":"Haque MIU, Mukherjee D, Stopka SA, Agar NYR, Hinkle J, Ovchinnikova OS. Deep learning on multimodal chemical and whole slide imaging data for predicting prostate cancer directly from tissue images. J Am Soc Mass Spectrom. 2023;34:227\u201335.","journal-title":"J Am Soc Mass Spectrom"},{"key":"1944_CR126","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.240336","volume":"7","author":"F Zabihollahy","year":"2025","unstructured":"Zabihollahy F, Wu HH, Sisk AE, Reiter RE, Raman SS, Fleshner NE, et al. Deep learning-based anatomy-aware morph model for registration of prostate whole-mount histopathology to MRI. Radiol Imag Cancer. 2025;7:e240336.","journal-title":"Radiol Imag Cancer"},{"key":"1944_CR127","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_438516","volume":"44","author":"IB Riaz","year":"2024","unstructured":"Riaz IB, Harmon S, Chen Z, Naqvi SAA, Cheng L. Applications of artificial intelligence in Prostate cancer care: a path to enhanced efficiency and outcomes. Am Soc Clin Oncol Educ Book. 2024;44:e438516.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1944_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071702","author":"SM Mutuku","year":"2022","unstructured":"Mutuku SM, Spotbeen X, Trim PJ, Snel MF, Butler LM, Swinnen JV. Unravelling prostate cancer heterogeneity using spatial approaches to lipidomics and transcriptomics. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14071702.","journal-title":"Cancers (Basel)"},{"key":"1944_CR129","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1055\/a-2175-4446","volume":"196","author":"T Bauerle","year":"2024","unstructured":"Bauerle T, Dietzel M, Pinker K, Bonekamp D, Zhang KS, Schlemmer HP, et al. Identification of impactful imaging biomarker: clinical applications for breast and prostate carcinoma. Rofo. 2024;196:354\u201362.","journal-title":"Rofo"},{"key":"1944_CR130","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.3390\/curroncol30040323","volume":"30","author":"SM Lanka","year":"2023","unstructured":"Lanka SM, Zorko NA, Antonarakis ES, Barata PC. Metastatic castration-resistant prostate cancer, immune checkpoint inhibitors, and beyond. Curr Oncol. 2023;30:4246\u201356.","journal-title":"Curr Oncol"},{"key":"1944_CR131","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40265-020-01456-z","volume":"81","author":"N Rathi","year":"2021","unstructured":"Rathi N, McFarland TR, Nussenzveig R, Agarwal N, Swami U. Evolving role of immunotherapy in metastatic castration refractory prostate cancer. Drugs. 2021;81:191\u2013206.","journal-title":"Drugs"},{"key":"1944_CR132","first-page":"1","volume":"40","author":"DVP de Almeida","year":"2020","unstructured":"de Almeida DVP, Fong L, Rettig MB, Autio KA. Immune checkpoint blockade for prostate cancer: niche role or next breakthrough? Am Soc Clin Oncol Educ Book. 2020;40:1\u201318.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1944_CR133","doi-asserted-by":"publisher","first-page":"194","DOI":"10.56434\/j.arch.esp.urol.20257802.27","volume":"78","author":"J Cao","year":"2025","unstructured":"Cao J. Effect of immune checkpoint inhibitors on advanced prostate cancer: a meta-analysis. Arch Esp Urol. 2025;78:194\u2013206.","journal-title":"Arch Esp Urol"},{"key":"1944_CR134","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029715","volume":"101","author":"XH Wang","year":"2022","unstructured":"Wang XH, Wang ZQ, Mu ZY, Zhu LP, Zhong CF, Guo S. The efficacy and safety of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2022;101:e29715.","journal-title":"Medicine (Baltimore)"},{"key":"1944_CR135","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/CCO.0000000000000719","volume":"33","author":"L Dong","year":"2021","unstructured":"Dong L, Myers KV, Pienta KJ. Understanding the tumor-immune microenvironment in prostate cancer. Curr Opin Oncol. 2021;33:231\u20137.","journal-title":"Curr Opin Oncol"},{"key":"1944_CR136","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2217\/pme-2021-0079","volume":"19","author":"A Ottini","year":"2022","unstructured":"Ottini A, Sepe P, Beninato T, Claps M, Guadalupi V, Verzoni E, et al. Biomarker-driven immunotherapy for precision medicine in prostate cancer. Per Med. 2022;19:51\u201366.","journal-title":"Per Med"},{"key":"1944_CR137","doi-asserted-by":"publisher","first-page":"65","DOI":"10.21037\/cco-19-207","volume":"9","author":"T Telvizian","year":"2020","unstructured":"Telvizian T, Mukherji D. Germline mutations and prostate cancer: is it time to change treatment algorithms? Chin Clin Oncol. 2020;9:65.","journal-title":"Chin Clin Oncol"},{"key":"1944_CR138","doi-asserted-by":"publisher","first-page":"1210673","DOI":"10.3389\/fonc.2023.1210673","volume":"13","author":"T Li","year":"2023","unstructured":"Li T, Qian X, Liu J, Xue F, Luo J, Yao G, et al. Radiotherapy plus immune checkpoint inhibitor in prostate cancer. Front Oncol. 2023;13:1210673.","journal-title":"Front Oncol"},{"key":"1944_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092187","author":"S Venkatachalam","year":"2021","unstructured":"Venkatachalam S, McFarland TR, Agarwal N, Swami U. Immune checkpoint inhibitors in prostate cancer. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13092187.","journal-title":"Cancers (Basel)"},{"key":"1944_CR140","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2021.08.011","volume":"81","author":"EM Kwan","year":"2022","unstructured":"Kwan EM, Spain L, Anton A, Gan CL, Garrett L, Chang D, et al. Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial. Eur Urol. 2022;81:253\u201362.","journal-title":"Eur Urol"},{"key":"1944_CR141","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/CBM-230090","volume":"40","author":"S Zhou","year":"2024","unstructured":"Zhou S, Wang B, Wei Y, Dai P, Chen Y, Xiao Y, et al. PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K\/AKT\/NFKB-P65\/PD-L1 signaling pathway. Cancer Biomark. 2024;40:47\u201359.","journal-title":"Cancer Biomark"},{"key":"1944_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104157","volume":"192","author":"BA Maiorano","year":"2023","unstructured":"Maiorano BA, Conteduca V, Catalano M, Antonuzzo L, Maiello E, De Giorgi U, et al. Personalized medicine for metastatic prostate cancer: the paradigm of PARP inhibitors. Crit Rev Oncol Hematol. 2023;192:104157.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1944_CR143","doi-asserted-by":"publisher","first-page":"1441222","DOI":"10.3389\/fonc.2024.1441222","volume":"14","author":"Y Xie","year":"2024","unstructured":"Xie Y, Xiao D, Li D, Peng M, Peng W, Duan H, et al. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer. Front Oncol. 2024;14:1441222.","journal-title":"Front Oncol"},{"key":"1944_CR144","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s00345-025-05760-9","volume":"43","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Maggs L, Zhou K, Zou C, Huang J, Wang X, et al. Piperlongumine enhances the antitumor efficacy of PD-1 inhibitors by inducing immunogenic cell death in prostate cancer cells. World J Urol. 2025;43:406.","journal-title":"World J Urol"},{"key":"1944_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101573","volume":"31","author":"S Tan","year":"2025","unstructured":"Tan S, Wang Q, Feng C, Pu X, Li D, Jiang F, et al. Biomimetic mineralized DCPA\/ anti-CD47 containing thermo-sensitive injectable hydrogel for bone-metastatic prostate cancer treatment. Mater Today Bio. 2025;31:101573.","journal-title":"Mater Today Bio"},{"key":"1944_CR146","first-page":"681","volume":"65","author":"J Braegelmann","year":"2024","unstructured":"Braegelmann J, Fuhrer D, Tan S. Endokrine nebenwirkungen von tumortherapien. Dtsch Med Wochenschr. 2024;65:681\u20139.","journal-title":"Dtsch Med Wochenschr"},{"key":"1944_CR147","volume":"96","author":"E Bosnali","year":"2024","unstructured":"Bosnali E, Akdas EM, Telli E, Teke K, Kara O. The role of immunotherapy in urological cancers. Arch Ital Urol Androl. 2024;96:12307.","journal-title":"Arch Ital Urol Androl"},{"key":"1944_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104556","volume":"205","author":"JR Puik","year":"2025","unstructured":"Puik JR, Le C, Kazemier G, Oprea-Lager DE, Swijnenburg RJ, Giovannetti E, et al. Prostate-specific membrane antigen as target for vasculature-directed therapeutic strategies in solid tumors. Crit Rev Oncol Hematol. 2025;205:104556.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1944_CR149","doi-asserted-by":"publisher","first-page":"175883592311704","DOI":"10.1177\/17588359231170474","volume":"15","author":"FC Martin","year":"2023","unstructured":"Martin FC, Dorff TB, Tran B. The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review. Ther Adv Med Oncol. 2023;15:17588359231170474.","journal-title":"Ther Adv Med Oncol"},{"key":"1944_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104643","volume":"208","author":"G Lin","year":"2025","unstructured":"Lin G, Elkashif A, Saha C, Coulter JA, Dunne NJ, McCarthy HO. Key considerations for a prostate cancer mRNA vaccine. Crit Rev Oncol Hematol. 2025;208:104643.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1944_CR151","first-page":"300","volume":"74","author":"W Lasek","year":"2021","unstructured":"Lasek W, Zapala L. Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology. Cent European J Urol. 2021;74:300\u20137.","journal-title":"Cent European J Urol"},{"key":"1944_CR152","doi-asserted-by":"publisher","first-page":"835","DOI":"10.7150\/jca.80803","volume":"14","author":"J Wang","year":"2023","unstructured":"Wang J, Zhou K, Zhu H, Wei F, Ma S, Kan Y, et al. Current status and progress of the development of prostate cancer vaccines. J Cancer. 2023;14:835\u201342.","journal-title":"J Cancer"},{"key":"1944_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12111273","author":"RD Marek","year":"2024","unstructured":"Marek RD, Halabi S, Wang ME, McBane J, Wei J, Wang T, et al. Vaccination against androgen receptor splice variants to immunologically target prostate cancer. Vaccines. 2024. https:\/\/doi.org\/10.3390\/vaccines12111273.","journal-title":"Vaccines"},{"key":"1944_CR154","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9070786","author":"L Guo","year":"2021","unstructured":"Guo L, Xie H, Zhang Z, Wang Z, Peng S, Niu Y, et al. Fusion protein vaccine based on Ag85B and STEAP1 induces a protective immune response against prostate cancer. Vaccines. 2021. https:\/\/doi.org\/10.3390\/vaccines9070786.","journal-title":"Vaccines"},{"key":"1944_CR155","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41585-023-00739-w","volume":"20","author":"I Rastogi","year":"2023","unstructured":"Rastogi I, Muralidhar A, McNeel DG. Vaccines as treatments for prostate cancer. Nat Rev Urol. 2023;20:544\u201359.","journal-title":"Nat Rev Urol"},{"key":"1944_CR156","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.euf.2022.12.002","volume":"9","author":"JK Parsons","year":"2023","unstructured":"Parsons JK, Pinto PA, Pavlovich CP, Uchio E, Nguyen MN, Kim HL, et al. A phase 2, double-blind, randomized controlled trial of PROSTVAC in prostate cancer patients on active surveillance. Eur Urol Focus. 2023;9:447\u201354.","journal-title":"Eur Urol Focus"},{"key":"1944_CR157","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008848","author":"A Muralidhar","year":"2024","unstructured":"Muralidhar A, Gamat-Huber M, Vakkalanka S, McNeel DG. Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-008848.","journal-title":"J Immunother Cancer"},{"key":"1944_CR158","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70294","volume":"13","author":"J He","year":"2024","unstructured":"He J, Wu J, Li Z, Zhao Z, Qiu L, Zhu X, et al. Immunotherapy vaccines for prostate cancer treatment. Cancer Med. 2024;13:e70294.","journal-title":"Cancer Med"},{"key":"1944_CR159","doi-asserted-by":"publisher","first-page":"1478331","DOI":"10.3389\/fphar.2025.1478331","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Yang F, Wang M, Huang X, Zeng X, Zhou L, et al. Unleashing the power of peptides in prostate cancer immunotherapy: mechanism, facts and perspectives. Front Pharmacol. 2025;16:1478331.","journal-title":"Front Pharmacol"},{"key":"1944_CR160","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/pros.23996","volume":"80","author":"X Shi","year":"2020","unstructured":"Shi X, Sun J, Li H, Lin H, Xie W, Li J, et al. Antitumor efficacy of interferon-gamma-modified exosomal vaccine in prostate cancer. Prostate. 2020;80:811\u201323.","journal-title":"Prostate"},{"key":"1944_CR161","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1158\/0008-5472.CAN-21-0163","volume":"81","author":"C Enriquez","year":"2021","unstructured":"Enriquez C, Cancila V, Ferri R, Sulsenti R, Fischetti I, Milani M, et al. Castration-induced downregulation of SPARC in stromal cells drives neuroendocrine differentiation of prostate cancer. Cancer Res. 2021;81:4257\u201374.","journal-title":"Cancer Res"},{"key":"1944_CR162","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1186\/s12967-025-06734-6","volume":"23","author":"PA Sacca","year":"2025","unstructured":"Sacca PA, Calvo JC. Advancing prostate cancer research: an exploration of periprostatic adipose stem cells. J Transl Med. 2025;23:794.","journal-title":"J Transl Med"},{"key":"1944_CR163","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12885-023-11771-9","volume":"24","author":"JS Enke","year":"2024","unstructured":"Enke JS, Gross M, Grosser B, Sipos E, Steinestel J, Lohr P, et al. SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer. BMC Cancer. 2024;24:65.","journal-title":"BMC Cancer"},{"key":"1944_CR164","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41420-025-02354-7","volume":"11","author":"G Wei","year":"2025","unstructured":"Wei G, Huang Y, Li W, Xie Y, Zhang D, Niu Y, et al. SREBF1-based metabolic reprogramming in prostate cancer promotes tumor ferroptosis resistance. Cell Death Discov. 2025;11:75.","journal-title":"Cell Death Discov"},{"key":"1944_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186622","author":"KN Tan","year":"2020","unstructured":"Tan KN, Avery VM, Carrasco-Pozo C. Metabolic roles of Androgen Receptor and Tip60 in androgen-dependent prostate cancer. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21186622.","journal-title":"Int J Mol Sci"},{"key":"1944_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101925","volume":"44","author":"G Wei","year":"2024","unstructured":"Wei G, Zhu H, Zhou Y, Pan Y, Yi B, Bai Y. Single-cell sequencing revealed metabolic reprogramming and its transcription factor regulatory network in prostate cancer. Transl Oncol. 2024;44:101925.","journal-title":"Transl Oncol"},{"key":"1944_CR167","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.canlet.2020.05.007","volume":"485","author":"J Wang","year":"2020","unstructured":"Wang J, Xu W, Wang B, Lin G, Wei Y, Abudurexiti M, et al. GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Lett. 2020;485:45\u201355.","journal-title":"Cancer Lett"},{"key":"1944_CR168","doi-asserted-by":"publisher","first-page":"2","DOI":"10.31083\/j.fbe1501002","volume":"15","author":"N Bhowmick","year":"2023","unstructured":"Bhowmick N, Posadas E, Ellis L, Freedland SJ, Vizio DD, Freeman MR, et al. Targeting glutamine metabolism in prostate cancer. Front Biosci (Elite Ed). 2023;15:2.","journal-title":"Front Biosci (Elite Ed)"},{"issue":"7","key":"1944_CR169","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1158\/0008-5472.CAN-20-2511","volume":"81","author":"MM Centenera","year":"2021","unstructured":"Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, et al. ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer. Cancer Res. 2021;81(7):1704\u201318.","journal-title":"Cancer Res"},{"key":"1944_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108337","volume":"242","author":"D Stehle","year":"2023","unstructured":"Stehle D, Barresi M, Schulz J, Feil R. Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: challenges and chances for cancer pharmacology and therapeutics. Pharmacol Ther. 2023;242:108337.","journal-title":"Pharmacol Ther"},{"key":"1944_CR171","doi-asserted-by":"publisher","DOI":"10.3390\/biom12111590","author":"SYC Choi","year":"2022","unstructured":"Choi SYC, Ribeiro CF, Wang Y, Loda M, Plymate SR, Uo T. Druggable metabolic vulnerabilities are exposed and masked during progression to castration resistant prostate cancer. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12111590.","journal-title":"Biomolecules"},{"key":"1944_CR172","doi-asserted-by":"publisher","DOI":"10.3390\/biom15060826","author":"Y Wang","year":"2025","unstructured":"Wang Y, Chen Y, Wang J. Role of tumor microenvironment in prostate cancer immunometabolism. Biomolecules. 2025. https:\/\/doi.org\/10.3390\/biom15060826.","journal-title":"Biomolecules"},{"key":"1944_CR173","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","volume":"29","author":"JK Lee","year":"2016","unstructured":"Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, et al. N-myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. Cancer Cell. 2016;29:536\u201347.","journal-title":"Cancer Cell"},{"key":"1944_CR174","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1084\/jem.20061104","volume":"203","author":"P Serafini","year":"2006","unstructured":"Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203:2691\u2013702.","journal-title":"J Exp Med"},{"key":"1944_CR175","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3389\/fonc.2020.01274","volume":"10","author":"JL Hsu","year":"2020","unstructured":"Hsu JL, Leu WJ, Hsu LC, Ho CH, Liu SP, Guh JH. Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling. Front Oncol. 2020;10:1274.","journal-title":"Front Oncol"},{"key":"1944_CR176","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1158\/1078-0432.CCR-20-1569","volume":"26","author":"S Muniyan","year":"2020","unstructured":"Muniyan S, Rachagani S, Parte S, Halder S, Seshacharyulu P, Kshirsagar P, et al. Sildenafil potentiates the therapeutic efficacy of docetaxel in advanced prostate cancer by stimulating NO-cGMP signaling. Clin Cancer Res. 2020;26:5720\u201334.","journal-title":"Clin Cancer Res"},{"key":"1944_CR177","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1158\/0008-5472.CAN-2148-2","volume":"64","author":"SL Ettinger","year":"2004","unstructured":"Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 2004;64:2212\u201321.","journal-title":"Cancer Res"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01944-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01944-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01944-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T20:02:34Z","timestamp":1766520154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01944-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":177,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1944"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01944-0","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"60"}}